Danaher beat Q2 estimates and raised its 2025 earnings guidance as bioprocessing strength and cost control boosted profit margins and revenue.
Latest Ratings for DHR
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 2022 | Wells Fargo | Maintains | Overweight | |
| Jan 2022 | Barclays | Maintains | Overweight | |
| Jan 2022 | Bernstein | Initiates Coverage On | Outperform |
